Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria

被引:51
|
作者
Zechmeister, Ingrid [1 ]
de Blasio, Birgitte Freiesleben [2 ]
Garnett, Geoff [3 ]
Neilson, Aileen Rae [4 ]
Siebert, Uwe [5 ,6 ,7 ,8 ]
机构
[1] Ludwig Boltzmann Inst Hlth Technol Assessment, A-1090 Vienna, Austria
[2] Univ Oslo, Inst Basic Med Sci, Oslo, Norway
[3] Univ London Imperial Coll Sci Technol & Med, Inst Microparasite Epidemiol, London, England
[4] Norwegian Knowledge Ctr Hlth Serv, Oslo, Norway
[5] Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth Med Decis Making & HTA, Hall In Tirol, LT, Austria
[6] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Decis Sci, Boston, MA 02115 USA
[7] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Inst Technol Assessment, Boston, MA USA
[8] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA
关键词
HPV-vaccination; Cost-effectiveness; Cervical cancer screening; ECONOMIC-EVALUATION; HPV VACCINATION; NATURAL-HISTORY; MODEL; TRANSFERABILITY; INFECTION; HEALTH; IMPACT; WOMEN;
D O I
10.1016/j.vaccine.2009.06.039
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: The study predicts long-term cervical cancer related population health and economic effects of introducing the HPV-vaccination for 12-year-old girls (and boys) in addition to current screening compared with screening only. Method: Health effects are predicted by a dynamic transmission model. Model results are used to calculate incremental cost-effectiveness ratios (ICER) in (sic) per life year gained (LYG) for a time-horizon between 2008 and 2060 from a public payer and a societal perspective. Results: Vaccination of girls results a discounted ICER of (sic) 64,000/LYG and (sic) 50,000/LYG from a payer's and societal perspectives respectively. The additional vaccination of boys increases the ICER to (sic) 311,000 and (sic) 299,000/LYG respectively. Results were most sensitive to vaccination price, discount rate and time-horizon. Conclusion: HPV-vaccination for girls should be cost-effective when adopting a longer time-horizon and a societal perspective. Applying a shorter time frame and a payer's perspective or vaccinating boys may not be cost-effective without reducing the vaccine price. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5133 / 5141
页数:9
相关论文
共 50 条
  • [21] Cost-effectiveness of human papillomavirus vaccination in Germany
    Oliver Damm
    Johannes Horn
    Rafael T. Mikolajczyk
    Mirjam E. E. Kretzschmar
    Andreas M. Kaufmann
    Yvonne Deleré
    Bernhard Ultsch
    Ole Wichmann
    Alexander Krämer
    Wolfgang Greiner
    Cost Effectiveness and Resource Allocation, 15
  • [22] A preliminary cost-effectiveness analysis of human papillomavirus vaccination in males for the prevention of oropharyngeal cancer
    Graham, Donna M.
    Isaranuwatchai, Wanrudee
    Habbous, Steven
    de Oliveira, Claire
    Liu, Geoffrey
    Siu, Lillian L.
    Hoch, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China
    Levin, Carol E.
    Sharma, Monisha
    Olson, Zachary
    Verguet, Stephane
    Shi, Ju-Fang
    Wang, Shao-Ming
    Qiao, You-Lin
    Jamison, Dean T.
    Kim, Jane J.
    VACCINE, 2015, 33 (24) : 2830 - 2841
  • [24] Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China
    Mo, Xiuting
    Tobe, Ruoyan Gai
    Wang, Lijie
    Liu, Xianchen
    Wu, Bin
    Luo, Huiwen
    Nagata, Chie
    Mori, Rintaro
    Nakayama, Takeo
    BMC INFECTIOUS DISEASES, 2017, 17
  • [25] Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China
    Xiuting Mo
    Ruoyan Gai Tobe
    Lijie Wang
    Xianchen Liu
    Bin Wu
    Huiwen Luo
    Chie Nagata
    Rintaro Mori
    Takeo Nakayama
    BMC Infectious Diseases, 17
  • [26] COST-EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS VACCINATION FOR PREVENTION OF CERVICAL CANCER IN RORAIMA, A BRAZILIAN AMAZONIC REGION STATE
    Balbinotto, G.
    Jardim, A.
    VALUE IN HEALTH, 2011, 14 (07) : A454 - A454
  • [27] Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore
    Phua, Lee Cheng
    Choi, Horace C. W.
    Wu, Joseph
    Jit, Mark
    Low, Jeffrey
    Ng, Kwong
    Pearce, Fiona
    Hall, Cameron
    Aziz, Mohamed Ismail Abdul
    VACCINE, 2021, 39 (16) : 2262 - 2270
  • [28] COST-EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS VACCINE FOR PREVENTION OF CERVICAL CANCER IN TAIWAN
    Liu, P. H.
    Wang, J. D.
    VALUE IN HEALTH, 2009, 12 (03) : A46 - A46
  • [29] A cost-effectiveness analysis of adult human papillomavirus vaccination strategies in Italy
    Cherif, Alhaji
    Palmer, Cody
    Senese, Francesca
    Bechini, Angela
    Salvati, Cristina
    Bonanni, Paolo
    Boccalini, Sara
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2025, 21 (01)
  • [30] Re: Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in the Netherlands Response
    de Kok, Inge M. C. M.
    van Ballegooijen, Marjolein
    Habbema, J. Dik F.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (05): : 359 - U90